Brought to you by 
Fujisawa licenses CVT's adenosine receptor agonist
03 Jun 2002
Executive Summary
Fujisawa Healthcare has licensed exclusive North American rights to CV Therapeutics' A2A adenosine receptor agonist CVT-3146, a second-generation cardiac stress agent, as well as a backup compound. The companies will jointly develop CVT-3146 for use in cardiac perfusion imaging, with CVT managing clinical development.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fujisawa licenses CVT's adenosine receptor agonist
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice